New Domestic Partnerships Help DualityBio Become China ADC Bellwether

 
• By Dexter Jie Yan

China's Duality Biologics, founded in 2020, has developed two-thirds of its clinical-stage antibody-drug conjugates by combining antibodies acquired from domestic peers with its proprietary linker-payload platform.

alliance
Chinese ADC players increasingly combining strengths in linker-payload platforms and antibodies • Source: Shutterstock

More from China

More from Focus On Asia